Category Archives: Innovation

Draft TB declaration: US, EU push against funding, delinkage pledges

Source: POLITICO PRO| June 12, 2018 The EU and U.S. are resisting concrete commitments on new funding for tuberculosis ahead of a high-level U.N. meeting about fighting the world’s top infectious killer. The two regions are also pushing to eliminate language … Continue reading

Posted in Delinkage, Tuberculosis (TB) | Leave a comment

Pharmaceutical corporations need to stop free-riding on publicly-funded research

by Jason Cone, The Hill The White House Council of Economic Advisers recently announced a strategy to curb high drug prices: force “free riding” countries abroad to pay more and watch the prices go down in America. That’s not how … Continue reading

Posted in Public funded research, Public research, R&D, Uncategorized | Leave a comment

Letter to US Secretary of Health and Human Services by US-based groups

25th May 2018 New Delhi On Friday, 18th May 2018  27 US-based groups sent a letter to the US Secretary of Health and Human Services calling for increased transparency in the biomedical innovation system. The letter can be read here. … Continue reading

Posted in Access to Medecines, Drug prices, Innovation, US debate on spiraling drug prices | Leave a comment

Breaking news for access to biological medicines – Brazilian court nixes biological drug eculizumab patent, says more could follow

Source: BioCentury | April 21, 2018 A Brazilian court unanimously ruled Friday to remove patent protection for Soliris eculizumab from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), opening the door for production of biosimilar versions in the country. In a statement, Brazil’s Attorney General Office said … Continue reading

Posted in Access to Medicins, Brazil Patent Reform, Open access, Patent, Regulation | Leave a comment

Draft Pharmaceutical Policy, 2017

Source: All India Drug Action Network (AIDAN) The Department of Pharmaceuticals has circulated a Draft Pharmaceutical Policy, 2017 which can be accessed here. The draft policy identifies the following key objectives: a. Making essential drugs accessible at affordable prices to the … Continue reading

Posted in API, Biologics/Biosimilars, Evergreening, Innovation, IPR, Patent, R&D, Uncategorized | Leave a comment

Stakeholder Intervention at 19th RCEP negotiations round- James Love, Knowledge Ecology International

These are the notes I used when providing the KEI comments at the July 25, 2017 civil society stakeholder forum at the 19th round of the RCEP negotiation. My name is James Love. I work for Knowledge Ecology International, an … Continue reading

Posted in Delinkage, FTA, IPR, Patent, R&D, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

IP watch: UN human rights council adopts access to medicines resolution

Source: IP Watch | June 23, 2017 The United Nations Human Rights Council today adopted a resolution on the right to health in relation to the UN 2030 Sustainable Development Goals (SDGs), including a call for medicines and vaccines access for … Continue reading

Posted in High Level Panel, Transfer of Technology, TRIPS, TRIPS flexibilities, Uncategorized | Leave a comment